Focal vs. full prostate treatment study
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether targeting only the visible cancer spots on MRI (focal therapy) works as well as treating the whole prostate, for men with small, moderate-risk prostate cancer that hasn't spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with prostate adenocarcinoma (the most common type of prostate cancer).
- Your cancer is Grade Group 2, 3, or 4 (meaning it is not the least aggressive or most aggressive).
- On MRI, the visible cancer area(s) are small: either one lesion no larger than 3 ml, or two lesions each no larger than 1.5 ml.
- The cancer does not appear to have spread outside the prostate (no gross EPE).
- Your doctor confirms that focal therapy can remove the entire visible cancer with a safe margin.
- You do not have a very aggressive (Grade Group 5) cancer, more than two significant lesions, or cancer in a hard-to-reach spot (like the very tip or base of the prostate).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a targeted treatment for prostate cancer that aims to treat only the cancer while sparing healthy tissue. It may be an option for men with low to medium risk prostate cancer.
This study tests a new way to treat prostate cancer that is not visible on MRI but is detected by a special PET scan. The treatment is a focal therapy that targets only the cancer while sparing healthy tissue, and it aims to control the cancer with fewer side effects.
This study is tracking men who choose focal therapy (a targeted treatment) for their localized prostate cancer. It aims to learn how well this treatment works and how it affects quality of life.
This registry tracks men with early-stage prostate cancer who choose focal therapy—a targeted treatment that destroys only the cancer area while preserving healthy prostate tissue. The study helps doctors understand how well this approach works and its safety.
This trial tests a gentler treatment called focal therapy that targets only the part of the prostate with cancer. It's for men whose prostate cancer has a Gleason score of 7, low PSA, and hasn't spread outside the prostate.
This trial tests a laser treatment that targets only the cancerous part of the prostate. It may be an option for men with intermediate-risk prostate cancer who do not want their entire prostate removed.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.